COT-21 EFFECT OF BEVACIZUMAB FOR PEDIATRIC HIGH GRADE GLIOMA

INTRODUCTION: Bevacizumab (BEV) therapy has been used for pediatric high grade glioma,however the evidence and effectiveness are not understood yet. METHODS: We report 7 cases (age 2 to 10 years old) of pediatric high grade glioma treated with BEV. One case is thalamic diffuse midline glioma H3K27 m...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Neurooncol Adv
Hlavní autoři: Tsukamoto, Yoshihiro, Natsumeda, Manabu, Okada, Masayasu, Eda, Takeyoshi, Yoshimura, Junichi, Okamoto, Kouichirou, Oishi, Makoto, Fujii, Yukihiko
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2019
Témata:
Abstracts
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7213162/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/noajnl/vdz039.201
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky